Tracked Medications

Central nervous system stimulant widely prescribed for attention deficit hyperactivity disorder and narcolepsy. Immediate-release formulation with 4–6 hour duration.

Dual-bead extended-release formulation designed to deliver prompt symptom relief followed by a second release for 10–12 hours of coverage.

Long-acting prodrug converted enzymatically to dextroamphetamine in the blood. Prescribed for ADHD and moderate-to-severe binge eating disorder.

Osmotic-release oral system (OROS) formulation providing steady all-day symptom control up to 12 hours without a steep midday crash.

First-line stimulant medication available in immediate-release tablets and sustained-release formulations for ADHD and narcolepsy.

The active d-enantiomer of methylphenidate, requiring lower milligram dosing. Available in immediate-release and XR bead formulations.

Selective norepinephrine reuptake inhibitor. Non-controlled alternative for ADHD management in adults and children.

Modern non-stimulant selective norepinephrine reuptake inhibitor approved for pediatric and adult ADHD.

Dextroamphetamine formulation available in immediate-release tablets and Spansule sustained-release capsules.

Triple-bead release profile delivering mixed amphetamine salts for up to 16 hours of daily ADHD coverage.

Evening-dosed methylphenidate taken before bed, with delayed release timed to take effect when waking up in the morning.

Once-weekly subcutaneous semaglutide injection approved for type 2 diabetes. Widely prescribed and tracked due to sustained national demand.

Higher-dose weekly semaglutide injection FDA-approved for chronic weight management and cardiovascular risk reduction.

First-in-class dual GIP and GLP-1 receptor agonist injection approved for type 2 diabetes, with potent glycemic control and weight reduction.

Dual GIP/GLP-1 receptor agonist formulation approved specifically for chronic weight management.

Daily oral tablet formulation of semaglutide for adults with type 2 diabetes who prefer non-injectable options.

Daily injectable GLP-1 receptor agonist approved for chronic weight management in adults and pediatric patients aged 12 and older.

Once-daily GLP-1 agonist injection for type 2 diabetes glycemic control and cardiovascular risk reduction.

Weekly pre-filled pen GLP-1 agonist injection prescribed to manage type 2 diabetes and reduce major adverse cardiovascular events.